CTRI/2021/12/038776进行中（未招募）3 期
Talapro-3: A phase 3, randomized, double-blind, study of Talazoparib with Enzalutamide versus Placebo with Enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male participants at least 18 years of age at screening.
- •2. Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell or signet cell features. If the participant does not have a prior histological diagnosis, a baseline de novo biopsy must be used to confirm the diagnosis and may also be used to support biomarker analysis.
- •3. Confirmation of DDR gene mutation status by prospective or historical analysis (with sponsor pre-approval) of blood (liquid biopsy) and/or de novo or archival tumor tissue using FoundationOne Liquid CDx or FoundationOne CDx.
- •4. Willing to provide tumor tissue when available (de novo or archived) for retrospective molecular profiling analysis, if not already provided as part of inclusion criterion 3.
- •5. Unless prohibited by local regulations or ethics committee decision, consent to a saliva sample collection for retrospective sequencing of the same DDR genes tested on tumor tissue and blood (liquid biopsy), or a subset thereof, and to serve as a germline control in identifying tumor mutations.
- •6. Surgically or medically castrated, with serum testosterone less or equal to 50 ng/dL (less or equal to 1.73 nmol/L) at screening. Ongoing ADT with a GnRH agonist or antagonist for participants who have not undergone bilateral orchiectomy must be initiated at least 4 weeks before randomization and must continue throughout the study.
- •7. Metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesions on CT or MRI scan (for soft tissue). Participants whose disease spread is limited to regional pelvic lymph nodes are not eligible. Note: a finding of superscan at baseline is exclusionary.
- •8. Prior docetaxel therapy for mCSPC (up to 6 cycles) is allowed (must be completed 2 weeks prior to randomization and all toxicities from treatment have resolved).
- •9. Treatment with estrogens, cyproterone acetate, or first-generation anti-androgens is allowed until randomization.
- •10. Other prior therapy allowed for mCSPC; <=6 months of ADT and <=3 months of approved NHT in mCSPC (ie, abiraterone + prednisone, apalutamide, or enzalutamide), if required prior to randomization.
排除标准
- •1. Other acute or chronic medical (concurrent disease, infection or co-morbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or laboratory abnormality that interferes with a participants ability to participate in the study, may increase the risk of associated with study participation or study treatment administration, or may interfere with the interpretation of study results, and, in the investigators judgment, make the participant inappropriate for entry into the study.
- •2. History of seizure or any condition (as assessed by investigator) that may predispose to seizure (eg, prior cortical stroke, significant brain trauma), including any history of loss of consciousness or transient ischemic attack within 12 months of randomization.
- •3. Major surgery (as defined by the investigator) within 2 weeks before randomization.
- •4. Known or suspected brain metastasis or active leptomeningeal disease.
- •5. Symptomatic or impending spinal cord compression or cauda equina syndrome.
- •6. Any history of MDS, AML, or prior malignancy except for the following:
- •(a) Carcinoma in situ or non-melanoma skin cancer.
- •(b) A cancer diagnosed and treated greater than or equal to 3 years before randomization with no subsequent evidence of recurrence.
- •(c) American Joint Committee on Cancer Stage 0 or Stage 1 cancer less than 3 years before randomization that has a remote probability of recurrence in the opinion of the investigator and the sponsor.
- •7. In the opinion of the investigator, any clinically significant gastrointestinal disorder affecting absorption.
- •8. Clinically significant cardiovascular disease, including any of the following:
- •(a) Myocardial infarction or symptomatic cardiac ischemia within 6 months before randomization.
- •(b) Congestive heart failure New York Heart Association class III or IV.
- •(c) History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes) within 1 year before screening.
- •(d) History of Mobitz II second degree or third-degree heart block unless a permanent pacemaker is in place.
- •(e) Hypotension as indicated by systolic blood pressure less than 86 mm Hg at screening.
- •(f) Bradycardia as indicated by a heart rate of less than 45 beats per minute on the screening electrocardiogram.
- •(g) Uncontrolled hypertension as indicated by systolic blood pressure greater than 170 mm Hg or diastolic blood pressure greater than 105 mm Hg at screening. However, participants can be rescreened after adequate control of blood pressure is achieved.
- •9. Active COVID-19 infection detected by viral test or based on clinical diagnosis (as assessed by investigator). Asymptomatic participants with no active COVID-19 infection detected but positive antibody tests, indicating past infection are allowed.
- •10. Prior ADT in the adjuvant/neoadjuvant setting, where the completion of ADT was less than 12 months prior to randomization and the total duration of ADT exceeded 36 months.
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPCMetastatic Castration-sensitive Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000248-23-SKPfizer Inc.599
进行中（未招募）
1 期
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPCEUCTR2021-000248-23-ITPFIZER INC550
进行中（未招募）
1 期
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPCMetastatic Castration-sensitive Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000248-23-ESPfizer Inc.550
进行中（未招募）
3 期
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCMetastatic Castration-sensitive Prostate CancerJPRN-jRCT2031210098Kawai Norisuke550
招募中
3 期
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC2024-510809-28-00Pfizer Inc.207